SUGAMMADEX SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sugammadex Sodium, and when can generic versions of Sugammadex Sodium launch?
Sugammadex Sodium is a drug marketed by Aspiro and Zydus Pharms and is included in two NDAs.
The generic ingredient in SUGAMMADEX SODIUM is sugammadex sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sugammadex Sodium
A generic version of SUGAMMADEX SODIUM was approved as sugammadex sodium by ASPIRO on June 9th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUGAMMADEX SODIUM?
- What are the global sales for SUGAMMADEX SODIUM?
- What is Average Wholesale Price for SUGAMMADEX SODIUM?
Summary for SUGAMMADEX SODIUM
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 32 |
| Clinical Trials: | 10 |
| Patent Applications: | 37 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SUGAMMADEX SODIUM |
| DailyMed Link: | SUGAMMADEX SODIUM at DailyMed |
Recent Clinical Trials for SUGAMMADEX SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Korea University Ansan Hospital | Phase 4 |
| YingHsuanTai | N/A |
| Zhejiang Cancer Hospital | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for SUGAMMADEX SODIUM
Paragraph IV (Patent) Challenges for SUGAMMADEX SODIUM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| BRIDION | Injection | sugammadex sodium | 200 mg/2 mL and 500 mg/5 mL | 022225 | 14 | 2019-12-16 |
US Patents and Regulatory Information for SUGAMMADEX SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspiro | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214337-001 | Jun 9, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214290-002 | Oct 4, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspiro | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214337-002 | Jun 9, 2023 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214290-001 | Oct 4, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
